Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections

Vaccine

Volumn 20, Issue 1-2, 2001, Pages 59-66

  Ghosh, Anirban ^a   Zhang, Wen Wei ^a   Matlashewski, Greg ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Leishmania donovani; Macrophage; Vaccine

Indexed keywords

GAMMA INTERFERON; PROTEIN A2; UNCLASSIFIED DRUG; VACCINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FLAGELLATE; GENETIC CODE; HUMORAL IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; INTERFERON PRODUCTION; LEISHMANIA DONOVANI; MOUSE; MULTIGENE FAMILY; NONHUMAN; PARASITE SURVIVAL; PARASITE VIRULENCE; PARASITOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTOZOAL INFECTION; SPLEEN CELL; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BLOTTING, WESTERN; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INTERFERON TYPE II; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SPLEEN; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS; VACCINATION;

EID: 0035850989     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00322-X     Document Type: Article

References (60)

1. Leishmaniasis
2. Visceral leishmanaisis: More prevalent and more problematic
3. Clinical spectrum of leishmaniasis
4. Visceral leishmaniasis in clinical practice
5. DDT resistance in P. Papatasi in Bihar
6. Leishmania-HIV interaction: Immunopathogenic mechanisms
7. Controlled field trails of a vaccine against New Word cuataneous leishmaniasis
8. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. Part I. Skin-test reactivity T-cell proliferation and interferon-γ production
9. Overview of human vaccine studies using killed L. major
10. Autoclaved Leishmania major vaccine for the prevention of visceral leishmaniasis: A randomised double blinded, BCG-controlled trial in Sudan
11. Development of a safe live Leishmania vaccine line by gene replacement
12. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis
13. Recombinant vaccinia virus expressing GP-46/M-2 protein against Leishmania infection
14. Human T cell responses to gp63, a surface antigen of Leishmania
15. Antigens shared by Leishmania species and Trypanosoma cruzi: Immunological comparison of the acidic ribosomal PO proteins
16. Expression cloning of a protective Leishmania antigen
17. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
18. The Leishmania donovani lipophosphoglycan T lymphocyte-reactive component is a tightly associated protein complex
19. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis
20. Analysis of the human T cell responsiveness to purified antigens of Leishmania: Lipophosphoglycan (LPG) and glycoprotein 63 (gp63)
21. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis
22. Stimulation of human T lymphocytes by Leishmania lipophosphoglycan-associated proteins
23. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis
24. Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine
25. Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani
26. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis
27. Developmental gene expression in Leishmania donovani: Differential cloning and analysis of an amastigote stage-specific gene
28. The developmental expression of Leishmania donovani A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3′ UTR
29. Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani
30. Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis
31. Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2
32. Intracellular infection by Leishmania donovani inhabits macrophage apoptosis
33. Leishmaniasis in hamster
34. Serodiagnosis of Leishmaniasis with recombinant orf-F antigen
35. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus iscoms
36. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis
37. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi
38. The capacity to produce IFN-γ rather than the presence of interleukin-4 determines theresistance and the degree of susceptibility to Leishmania donovani infection in mice
39. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production
40. Current status of immunological adjuvants
41. Immunological responses of L. donovani infection in mice and significance of T cell in resistance to experimental leishmaniasis
42. Evaluation of antibody responses in American visceral leishmaniasis by ELISA and immunoblot
43. Polyclonal B cell activation, circulating immune complexes and autoimmunity in human Aerican visceral leishmaniasis
44. Diminished in vitro production of interleukin-1 and tumor necrosis factor during acute visceral leishmaniasis and recovery after therapy
45. Experimental visceral leishmaniasis: Production of interleukin 2 and interferon-γ, tissue immune reaction, and response to treatment with interleukin 2 and interferon-γ
46. Immunological regulation and control of experimental leishmaniasis
47. Reciprocal expression of Interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis, evidence for expansion of distinct helper T-cell subsets
48. + lymphocytes in vivo during healing and progressive murine leishmaniasis
49. Helper T-cell subsets in mouse leishmaniasis: Induction, expansion and effector function
50. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens
51. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis
52. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-γ
53. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis
54. Roles of CR3 and mannose receptors in the attachment and ingestion of Leishmania donovani by human mononuclear phagocytes
55. Interaction of Leishmania gp63 with cellular receptors for fibronectin
56. Immune adherence-mediated opsonophagocytosis: The mechanism of Leishmania infection
57. Leishmania amazonensis: The phagocytosis of amastigotes by macrophages
58. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis
59. Comparison of receptors required for entry of Leishmania major amastigotes into macrophages